Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Hepato-Biliary

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Intervention not reported

All‐cause mortality at maximum · adults with compensated or decompensated advanced chronic liver disease

It is very uncertain whether the intervention changes all‐cause mortality at maximum (very low certainty).

1 finding from 1 review

Granulocyte colony‐stimulating factor with or without stem or progenitor cell or growth factors infusion for people… 2023 · Cochrane Headline outcomes only
RR 0.53 [0.38, 0.72]
20 studies · 1419 participants
Very low

Direct‐acting antivirals vs control

All‐cause mortality maximum · adults with chronic hepatitis C

It is very uncertain whether direct‐acting antivirals changes all‐cause mortality at maximum compared with control (very low certainty).

1 finding from 1 review

Direct‐acting antivirals for chronic hepatitis C 2017 · Cochrane Headline outcomes only
OR 3.72 [0.53, 26.18]
11 studies · 2996 participants
Very low

Direct‐acting antivirals withdrawn from the market vs control

All‐cause mortality maximum · adults with chronic hepatitis C

It is very uncertain whether direct‐acting antivirals withdrawn from the market changes all‐cause mortality at maximum compared with control (very low certainty).

1 finding from 1 review

Direct‐acting antivirals for chronic hepatitis C 2017 · Cochrane Headline outcomes only
OR 0.64 [0.23, 1.79]
5 studies · 3045 participants
Very low

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma

External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).

1 finding from 1 review

External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
RR 0.51 [0.41, 0.62]
9 studies · 786 participants
Low